Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants

Abstract Background The emergence of SARS-CoV-2 Omicron subvariants has raised questions regarding resistance to immunity by natural infection or immunization. We examined the sensitivity of Delta and Omicron subvariants (BA.1, BA.1.1, BA.2, BA.2.12.1, BA.4/5, and BA.3) to neutralizing antibodies fr...

Full description

Bibliographic Details
Main Authors:	Xue-Jun Wang, Lin Yao, Hong-Yun Zhang, Ka-Li Zhu, Jing Zhao, Bing-Dong Zhan, Yi-Ke Li, Xue-Juan He, Cong Huang, Zhuang-Ye Wang, Ming-Dong Jiang, Peng Yang, Yang Yang, Guo-Lin Wang, Sheng-Qi Wang, Er-Hei Dai, Hui-Xia Gao, Mai-Juan Ma
Format:	Article
Language:	English
Published:	BMC 2022-12-01
Series:	Genome Medicine
Subjects:	SARS-CoV-2 Omicron subvariants Breakthrough infection Vaccination neutralization Fusogenicity Infectivity
Online Access:	https://doi.org/10.1186/s13073-022-01151-6

Similar Items

Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants
by: Panke Qu, et al.
Published: (2023-02-01)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
by: Shuai Xia, et al.
Published: (2023-12-01)

Differentiating Cell Entry Potentials of SARS-CoV-2 Omicron Subvariants on Human Lung Epithelium Cells
by: Revansiddha H. Katte, et al.
Published: (2024-03-01)

Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study
by: Cheng Cao, et al.
Published: (2023-08-01)

Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay
by: Mako Toyoda, et al.
Published: (2023-08-01)

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination1
by: Hongyu Wang, et al.
Published: (2023-12-01)

The fourth COVID-19 vaccine dose increased the neutralizing antibody response against the SARS-CoV-2 Omicron (B.1.1.529) variant in a diverse Brazilian population
by: Jéssica Pires Farias, et al.
Published: (2023-12-01)

Immune Evasion of SARS-CoV-2 Omicron Subvariants
by: Hanzhong Ke, et al.
Published: (2022-09-01)

Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants
by: Yaning Li, et al.
Published: (2023-06-01)

Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave
by: Shohei Yamamoto, et al.
Published: (2023-03-01)

Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants
by: Chiranjib Chakraborty, et al.
Published: (2023-03-01)

An imported human case with the SARS-CoV-2 Omicron subvariant BA.2.75 in Yunnan Province, China
by: Meiling Zhang, et al.
Published: (2022-12-01)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
by: Srijan Chatterjee, et al.
Published: (2023-06-01)

Computational Investigation of Selected Spike Protein Mutations in SARS-CoV-2: Delta, Omicron, and Some Circulating Subvariants
by: Urmi Roy
Published: (2023-12-01)

Fusogenic Viruses in Oncolytic Immunotherapy
by: Teresa Krabbe, et al.
Published: (2018-06-01)

Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
by: Samuel M.S. Cheng, et al.
Published: (2024-03-01)

Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort
by: Jianliang Huang, et al.
Published: (2023-10-01)

Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau
by: Cong Xu, et al.
Published: (2023-01-01)

Kinetics of SARS-CoV-2 neutralizing antibodies in Omicron breakthrough cases with inactivated vaccination: Role in inferring the history and duration of infection
by: Aidibai Simayi, et al.
Published: (2023-01-01)

XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness
by: Okesanya Olalekan John, B'MLS, et al.
Published: (2023-12-01)

Vitamin D levels and clinical outcomes of SARS-CoV-2 Omicron subvariant BA.2 in children: A longitudinal cohort study
by: Denggao Peng, et al.
Published: (2022-07-01)

Assessment of antibody responses against SARS-CoV-2 in unvaccinated individuals and vaccinees from Omicron-BA.2 infection in Zhaoqing, Guangdong Province, China
by: Huan Zhang, et al.
Published: (2022-11-01)

Comparison of the replication and neutralization of different SARS‐CoV‐2 Omicron subvariants in vitro
by: Yaqing Zhang, et al.
Published: (2023-02-01)

Characteristics of the First 284 Patients Infected with the SARS-CoV-2 Omicron BA.2 Subvariant at a Single Center in the Apulia Region of Italy, January–March 2022
by: Daniela Loconsole, et al.
Published: (2022-04-01)

Redistribution and Activation of CD16brightCD56dim NK Cell Subset to Fight against Omicron Subvariant BA.2 after COVID-19 Vaccination
by: Huiyun Peng, et al.
Published: (2023-04-01)

Immune Response after SARS-CoV-2 Infection with Residual Post-COVID Symptoms
by: Tanyaporn Pongkunakorn, et al.
Published: (2023-08-01)

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
by: Shohei Yamamoto, et al.
Published: (2023-05-01)

Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong KongResearch in context
by: Runhong Zhou, et al.
Published: (2023-03-01)

Structural Insights into Membrane Fusion Mediated by Convergent Small Fusogens
by: Yiming Yang, et al.
Published: (2021-01-01)

Development of a panel of three multiplex allele-specific qRT-PCR assays for quick differentiation of recombinant variants and Omicron subvariants of SARS-CoV-2
by: Jianguo Li, et al.
Published: (2022-08-01)

COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
by: Nungruthai Suntronwong, et al.
Published: (2022-03-01)

Differences in clinical characteristics and liver injury between patients diagnosed with the Omicron subvariant BA.5.2 and the prototype of SARS-CoV-2: a single center retrospective study
by: Jie Li, et al.
Published: (2023-08-01)

SARS-CoV-2 Antibody Response against Mild-to-Moderate Breakthrough COVID-19 in Home Isolation Setting in Thailand
by: Pichanun Mongkolsucharitkul, et al.
Published: (2022-07-01)

Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
by: Evropi Amanatidou, et al.
Published: (2022-06-01)

Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study
by: Carson K. L. Lo, et al.
Published: (2024-01-01)

Omicron infection-associated T- and B-cell immunity in antigen-naive and triple-COVID-19-vaccinated individuals
by: Joana Barros-Martins, et al.
Published: (2023-05-01)

The Omicron variant of concern: The genomics, diagnostics, and clinical characteristics in children
by: Djatnika Setiabudi, et al.
Published: (2022-08-01)

Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe
by: Evangelia Georgia Kostaki, et al.
Published: (2022-12-01)

Effect of second booster vaccination on clinical outcomes of Omicron-variant breakthrough infection: A propensity score matching cohort study
by: Denggao Peng, et al.
Published: (2024-01-01)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
by: Eveline Santos da Silva, et al.
Published: (2023-02-01)